Novartis

Novartis's stock slid 10% on September 8 after two late-stage drug failures, including the Avidity Biosciences acquisition's centerpiece. The company faces a major patent cliff and safety concerns with its CAR-T cell therapy, while its $1.1 billion Myricx Bio acquisition remains a wildcard. Watch for further pipeline updates and investor reactions to these setbacks.